Quality of Life in Presbyopic Patients Who Are Treated With Qlosi

Eligibility Criteria

• * Subjects who are 45-64 years old (inclusive) at the time of screening.
• * Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.
• * Be able and willing to follow all instructions and attend study visits.
• * Have text messaging capabilities on their phone.
• * Self-reported complaints of near vision blur when fully corrected at distance.
• * Study confirmed near add that is between +0.75 D to +2.00 D OD/OS (inclusive).
• * Spherical distance prescription between +1.00 D to -4.00 D OD/OS (inclusive).
• * Cylinder power less than or equal to -1.00 D OD/OS.
• * Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20/20 Snellen equivalent) or better OD/OS.
• * Known hypersensitivity to any ingredient in the study drops.
• * Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).
• * Any use of prescription eye drops 1 week before screening or during the study.
• * Any past use of the study drops.
• * Any contact lens use for the duration of the study.
• * Artificial tears or lubricant eye drops use on the day of or during any study visits.
• * Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could confound study results.
• * Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.
• * A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.
• * Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).